AEON Biopharma, Inc. — fact timeline

AEON Biopharma, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-17 meeting.

“Proposal 2: The stockholders of the Company ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. The voting results for this proposal were as follows: ​ ​ ​ ​ ​ ​ ​ For ​ Against ​ Abstain ​ Broker Non-Vote 21,502,418 ​ 18,217 ​ 1,498 ​ —”

AEON Biopharma, Inc. shareholders approved Election of Class III Directors at the 2026-06-17 meeting.

“Proposal 1: The stockholders of the Company elected each of Marc Forth and Seongsoo Park as Class III directors of the Company’s board of directors (the “Class III Directors”) for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. The voting results with respect to the election of the Class III Directors were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nominee ​ Term Expiring ​ For ​ Withheld ​ Broker Non-Vote Marc Forth ​ 2029 ​ 13,297,322 ​ 27,738 ​ 8,197,073 Seongsoo Park ​ 2029 ​ 13,117,299 ​ 207,761 ​ 8,197,073”

AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 14, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the first quarter ended March 31, 2026.”

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(ii)).

“March 31, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) received an additional written notice of non-compliance (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires stockholders’ equity of $4.0 million or more if a listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reporte”

AEON Biopharma, Inc. reported financial results for the year ended December 31, 2025.

“On March 30, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the year ended December 31, 2025.”

AEON Biopharma, Inc. issued warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share of warrant to Daewoong Pharmaceutical Co., LTD..

“(iii) warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share”

AEON Biopharma, Inc. issued $1,500,000 of convertible note to Daewoong Pharmaceutical Co., LTD..

“(ii) a new senior secured convertible note in a principal amount of $1,500,000 (the “New Note”)”

AEON Biopharma, Inc. issued 11,236,631 pre-funded warrants to purchase shares of Common Stock of warrant to Daewoong Pharmaceutical Co., LTD..

“on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the “Exchange Shares”)”

AEON Biopharma, Inc. issued 11,918,380 newly issued shares of Common Stock of common stock to Daewoong Pharmaceutical Co., LTD..

“on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the “Exchange Shares”)”

AEON Biopharma, Inc. entered into Exchange Agreement with Daewoong Pharmaceuticals, Co., LTD (effective 2025-12-15).

“On December 15, 2025, the Company and AEON Biopharma Sub, Inc., a Delaware corporation (the “AEON Sub”) entered into an Exchange Agreement (the “Exchange Agreement”) with Daewoong consistent with the terms of the Term Sheet pursuant to which the Convertible Notes held by Daewoong would be exchanged for (i) newly issued shares of Common Stock of the Company”

AEON Biopharma, Inc. issued pre-funded warrants of warrant to Daewoong Pharmaceuticals, Co., LTD for in lieu of Common Stock shares exceeding 49.99% beneficial ownership.

“pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of any shares of Common Stock that would result in Daewoong’s beneficial ownership of Common Stock exceeding 49.99%”

AEON Biopharma, Inc. issued $1,500,000 of convertible note to Daewoong Pharmaceuticals, Co., LTD for exchange of existing Convertible Notes.

“a new senior secured convertible note for $1,500,000 (the “New Convertible Note”)”

AEON Biopharma, Inc. issued up to 8,000,000 shares of warrant to Daewoong Pharmaceuticals, Co., LTD for exercise price of $1.09392 per share.

“warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share (the “Common Stock Warrant”).”

AEON Biopharma, Inc. issued approximately 23.1 million of common stock to Daewoong Pharmaceuticals, Co., LTD for exchange of Convertible Notes.

“On December 15, 2025, the Company and AEON Biopharma Sub, Inc., a Delaware corporation (the “AEON Sub”) entered into an Exchange Agreement (the “Exchange Agreement”) with Daewoong consistent with the terms of the Term Sheet pursuant to which the Convertible Notes held by Daewoong would be exchanged for (i) newly issued shares of Common Stock of the Company”

AEON Biopharma, Inc. issued Pre-Funded Warrants, Warrants and True-Up Warrants of warrant to certain investors for $0.0001 per share for Pre-Funded Warrants, $1.09392 per share for Warrants.

“The Pre-Funded Warrants are being offered in lieu of shares of Common Stock and each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share.”

AEON Biopharma, Inc. issued 1,964,905 Shares of common stock to certain investors for $0.9116 per Share.

“to purchase shares of Common Stock, and (iv) True-Up Warrants (as defined below) to purchase shares of Common Stock. The purchase price to be paid by the Investors will be $0.9116 per Share (or $0.9115 per Pre-Funded Warrant in lieu of Shares). The first closing of the Private Placement is expected to occur the week of November 17, 2025 (the “First”

AEON Biopharma, Inc. received a nyse_american extension granted notice regarding other (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“April 22, 2025, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Plan was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 3, 2026 (the “Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide d”

Jost Fisher changed role as Interim President and Chief Executive Officer at AEON Biopharma, Inc..

“Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.”

Robert Bancroft was appointed as Chief Executive Officer, President and Principal Executive Officer at AEON Biopharma, Inc..

“On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.”

Jennifer Sy was appointed as Chief Accounting Officer and principal financial officer at AEON Biopharma, Inc..

“On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.”

Jost Fischer was appointed as Interim President, Chief Executive Officer and principal executive officer at AEON Biopharma, Inc..

“On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.”

Jost Fischer was appointed as Interim Chief Executive Officer at AEON Biopharma, Inc..

“The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.”

Marc Forth resigned as President and Chief Executive Officer at AEON Biopharma, Inc..

“On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.”

AEON Biopharma, Inc.: Approved reverse stock split at a ratio of 1-for-72 (effective 2025-02-26).

“The Company intends to file the Charter Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split on February 25, 2025, to become effective at 12:01 a.m. Eastern Time on February 26, 2025 (the “Effective Date”).”

AEON Biopharma, Inc.: Increased authorized shares of common stock from 500,000,000 to 1,040,000,000 (effective 2025-02-25).

“The amendment to the Certificate of Incorporation will be filed with the Secretary of State of the State of Delaware on February 25, 2025 and became effective on such date.”

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).

“recent fiscal years (the “Minimum Requirement”), as defined in Section 1003(a)(i) of the Company Guide. Pursuant to the Notice, the Company reported a stockholders’ deficit of $32.1 million at September 30, 2024 and has had losses in the two most recent fiscal years ended December 31, 2023 based on the Company’s Annual Report on Form 10-K/A filed with the U.S.”

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).

“February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w”

AEON Biopharma, Inc.: Changed quorum requirement for shareholder meetings from a majority to 33.34% of voting power (effective 2024-12-18).

“On December 18, 2024, Aeon Biopharma, Inc. (the “Company”) amended its amended and restated bylaws (the “Bylaws”) to change the quorum requirement for shareholder meetings from a majority to 33.34% of the voting power of the Company’s outstanding shares entitled to vote at a meeting.”

Jennifer Sy was appointed as principal accounting officer at AEON Biopharma, Inc..

“On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.”

Marc Forth was appointed as principal financial officer at AEON Biopharma, Inc..

“On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.”

Peter Reynolds was terminated as Chief Financial Officer at AEON Biopharma, Inc..

“On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.”

AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2024.

“AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the fiscal quarter ended March 31, 2024.”

AEON Biopharma, Inc. reported that prior financial statements should not be relied upon.

“The Company's management and the Board have discussed the matters described herein with KPMG LLP, the Company's independent registered public accounting firm. The identified error had no impact on the Company’s cash balances or operating cash flows for the quarter ended September 30, 2023 nor the year ended December 31, 2023.”

AEON Biopharma, Inc. incurred convertible notes of $10.0 million with Daewoong Pharmaceutical Co., LTD. at annual rate of 15.79% maturing April 12, 2027.

“on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $10.0 million”

AEON Biopharma, Inc. entered into Convertible Note with Daewoong Pharmaceutical Co., LTD. valued at $10.0 million (effective 2024-04-12).

“on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $10.0 million.”

Seongsoo Park was appointed as Class III director at AEON Biopharma, Inc..

“the Board of Directors (the “Board”) of the Company appointed Seongsoo Park as a Class III director of the Board, effective as of April 12, 2024.”

AEON Biopharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.”

AEON Biopharma, Inc. incurred convertible notes of $5,000,000 with Daewoong Pharmaceutical Co., LTD. at 15.79% maturing March 24, 2027.

“on March 24, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $5,000,000”

AEON Biopharma, Inc. entered into Subscription Agreement with Daewoong Pharmaceutical Co., LTD. valued at up to $15.0 million (effective 2024-03-19).

“on March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes in the principal amount of up to $15.0 million”

AEON Biopharma, Inc. incurred convertible notes of $15.0 million with Daewoong Pharmaceutical Co., LTD. at 15.79% maturing three years from the funding date.

“On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million”

AEON Biopharma, Inc. entered into Subscription Agreement with Daewoong Pharmaceutical Co., LTD. valued at $15.0 million (effective 2024-03-19).

“On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million”

AEON Biopharma, Inc. reported that prior financial statements should not be relied upon.

“concluded that the Company’s previously issued financial statements as of and for the three and nine months ended September 30, 2023, included in the Company’s Quarterly Report on Form 10-Q filed on November 13, 2023 (the “Form 10-Q”) and its Registration Statement on Form S-1 (File No. 333-274094) filed on November 24, 2023 (as amended, the “Registration Statement”), should no longer be relied upon”

AEON Biopharma, Inc. reported financial results for the third quarter ended September 30, 2023.

“AEON Biopharma, Inc. (the "Company") announced financial results for the fiscal quarter ended September 30, 2023.”

AEON Biopharma, Inc. engaged KPMG LLP as its auditor.

“On September 28, 2023, the Audit Committee recommended, and the Board of Directors of the Company approved, the engagement of KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm for the Company's fiscal year ending December 31, 2023.”

AEON Biopharma, Inc. dismissed Ernst & Young LLP as its auditor.

“On September 28, 2023 (the "Dismissal Date"), the Audit Committee of the Board of Directors of AEON Biopharma, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the independent registered public accounting firm for AEON Biopharma Sub, Inc., (the "Operating Company"), effective immediately.”

AEON Biopharma, Inc.: Company ceased being a shell company as a result of the Business Combination.

“As a result of the Business Combination, the Company ceased being a shell company.”

AEON Biopharma, Inc.: New Code of Business Conduct and Ethics adopted on July 21, 2023 (effective 2023-07-21).

“on July 21, 2023, AEON’s board of directors approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of AEON.”

AEON Biopharma, Inc.: Amended and Restated Bylaws approved and adopted on July 21, 2023, effective immediately prior to the Business Combination (effective 2023-07-21).

“On July 21, 2023, the Board approved and adopted the Amended and Restated Bylaws of AEON (the “Bylaws”), which became effective immediately prior to the completion of the Business Combination.”

AEON Biopharma, Inc.: Amended and Restated Certificate of Incorporation effective July 21, 2023 (effective 2023-07-21).

“The Amended and Restated Certificate of Incorporation of AEON (the “Certificate of Incorporation”), which became effective upon filing with the Secretary of State of the State of Delaware on July 21, 2023 includes the amendments proposed by the Charter Proposals.”

AEON Biopharma, Inc. underwent a change of control involving Old AEON Biopharma, Inc. (closed 2023-07-21).

“Pursuant to the terms and subject to the conditions set forth in the Business Combination Agreement, following the Special Meeting, on July 21, 2023 (the “Closing Date”), the Transactions were consummated (the “Closing”).”